» Articles » PMID: 28593992

Insights into Hunter Syndrome from the Structure of Iduronate-2-sulfatase

Overview
Journal Nat Commun
Specialty Biology
Date 2017 Jun 9
PMID 28593992
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Hunter syndrome is a rare but devastating childhood disease caused by mutations in the IDS gene encoding iduronate-2-sulfatase, a crucial enzyme in the lysosomal degradation pathway of dermatan sulfate and heparan sulfate. These complex glycosaminoglycans have important roles in cell adhesion, growth, proliferation and repair, and their degradation and recycling in the lysosome is essential for cellular maintenance. A variety of disease-causing mutations have been identified throughout the IDS gene. However, understanding the molecular basis of the disease has been impaired by the lack of structural data. Here, we present the crystal structure of human IDS with a covalently bound sulfate ion in the active site. This structure provides essential insight into multiple mechanisms by which pathogenic mutations interfere with enzyme function, and a compelling explanation for severe Hunter syndrome phenotypes. Understanding the structural consequences of disease-associated mutations will facilitate the identification of patients that may benefit from specific tailored therapies.

Citing Articles

Structural and Functional Integration of Tissue-Nonspecific Alkaline Phosphatase Within the Alkaline Phosphatase Superfamily: Evolutionary Insights and Functional Implications.

Imam I, Rautureau G, Violot S, Drevet Mulard E, Magne D, Ballut L Metabolites. 2024; 14(12).

PMID: 39728440 PMC: 11677397. DOI: 10.3390/metabo14120659.


Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants.

Zanetti A, DAvanzo F, Tomanin R Hum Genomics. 2024; 18(1):134.

PMID: 39617925 PMC: 11610362. DOI: 10.1186/s40246-024-00701-w.


Boolean Modeling of Biological Network Applied to Protein-Protein Interaction Network of Autism Patients.

Nezamuldeen L, Jafri M Biology (Basel). 2024; 13(8).

PMID: 39194544 PMC: 11352122. DOI: 10.3390/biology13080606.


Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond.

Zanetti A, Tomanin R BioDrugs. 2024; 38(5):639-655.

PMID: 39177874 PMC: 11358193. DOI: 10.1007/s40259-024-00675-0.


Mature neurons from iPSCs unveil neurodegeneration-related pathways in mucopolysaccharidosis type II: GSK-3β inhibition for therapeutic potential.

Chen T, Lin S, Huang D, Huang H, Tsai F, Lee L Cell Death Dis. 2024; 15(4):302.

PMID: 38684682 PMC: 11058230. DOI: 10.1038/s41419-024-06692-9.


References
1.
Sidhu N, Schreiber K, Propper K, Becker S, Uson I, Sheldrick G . Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA. Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 5):1321-35. PMC: 4014121. DOI: 10.1107/S1399004714002739. View

2.
Wilson P, Morris C, Anson D, Occhiodoro T, Bielicki J, Clements P . Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A. 1990; 87(21):8531-5. PMC: 54990. DOI: 10.1073/pnas.87.21.8531. View

3.
Ferro D, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V . Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res. 1990; 195(2):157-67. DOI: 10.1016/0008-6215(90)84164-p. View

4.
King C, Garza E, Mazor R, Linehan J, Pastan I, Pepper M . Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci U S A. 2014; 111(23):8577-82. PMC: 4060723. DOI: 10.1073/pnas.1321126111. View

5.
Lieberman R, Wustman B, Huertas P, Powe Jr A, Pine C, Khanna R . Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2006; 3(2):101-7. DOI: 10.1038/nchembio850. View